Loading
Life sciences · Journal article
Emerging Microbes & Infections · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Carbapenem-resistant Gram-negative bacteria (CRGNB) pose a severe global health threat. Carbapenem-resistant Acinetobacter baumannii (CRAB) is one of the most critical threats among CRGNB, and effective non-antibiotic therapeutic strategies are urgently needed. Bactericidal/permeability-increasing protein (BPI)-derived molecules display antibacterial and endotoxin-neutralizing activities against Gram-negative bacteria, whereas CXCL8(3-72) K11R/G31P (G31P), an analog of CXCL8 with the mutations of CXCL8 at K11 and G31 positions, could antagonize ELR-CXC chemokine-mediated neutrophil chemotaxis. Here, we engineered a dual-function fusion protein, G31P-BPI233, to combine BPI-mediated antibacterial activity with modulation of neutrophil-driven inflammation. Recombinant G31P-BPI233 was expressed in CHO-K1 cells and characterized through safety evaluation, endotoxin neutralization, bactericidal, serum killing, neutrophil killing, chemotaxis, cytokine, phagocytosis, and NET-associated marker assays, followed by validation in mouse models of CRAB septicemia and pneumonia. Short-term safety assessment suggested preliminary tolerability over 24 h, while G31P-BPI233 reduced residual endotoxin activity and exhibited concentration-dependent bactericidal activity against multiple Gram-negative bacteria. At molar-matched doses, it retained G31P-mediated inhibition of neutrophil migration and BPI233-associated bactericidal and cytokine-suppressive activities. In CRAB models, G31P-BPI233 improved septicemia survival and reduced pneumonia-associated bacterial burden and inflammatory injury, with endpoint-specific advantages over G31P, BPI233, or their equimolar mixture. Several pneumonia outcomes did not differ significantly between G31P-BPI233 and colistin. Mechanistic studies using BPI-deficient mice further demonstrated that endogenous BPI contributes to bacterial clearance, endotoxin control, and neutrophil maturation and effector function during CRAB infection. Collectively, these findings identify G31P-BPI233 as a promising host-directed antibacterial fusion protein for severe CRAB infection, with potential translational implications for the broader management of CRGNB.